Literature DB >> 28469953

MicroRNA-1468-5p inhibits glioma cell proliferation and induces cell cycle arrest by targeting RRM1.

Kuan Jiang1,2, Tongle Zhi1, Wenhui Xu2, Xiupeng Xu1, Weining Wu1, Tianfu Yu1, Er Nie1, Xu Zhou1, Zhongyuan Bao1, Xin Jin1, Junxia Zhang1, Yingyi Wang1, Ning Liu1.   

Abstract

MicroRNAs are associated with different types of cancers. In this study, we found that miR-1468-5p could inhibit growth and cell cycle progression in glioma by targeting ribonucleotide reductase large subunit M1 (RRM1). First, we analyzed miR-1468-5p expression in different glioma grades and the prognostic significance of its expression in glioblastoma multiform patients from the Chinese Glioma Genome Atlas. Then, we expressed miR-1468-5p in U87 and U251 cells and assessed the effects on proliferation and cell cycle progression using cell counting kit-8, colony formation, EdU and flow cytometry assays. Western blotting and luciferase reporter assays identified RRM1 as a novel direct target of miR-1468-5p. Experiments to determine the role of RRM1 in glioma showed that RRM1 expression was significantly higher in glioma than in normal brain tissues, and silencing RRM1 with small-interfering RNAs decreased proliferation and suppressed cell cycle progression, which indicated that RRM1 had pro-tumor functions. miR-1468-5p overexpression suppressed RRM1 expression, reduced glioma cell proliferation and induced cell cycle arrest, which was partially rescued by forced RRM1 expression. In summary, our study revealed that the regulatory mechanism of miR-1468-5p in glioma cell cycle progression involved direct regulation of RRM1 expression, suggesting that RRM1 may be a potential therapeutic target for glioma.

Entities:  

Keywords:  RRM1; cell cycle; glioma; miR-1468-5p; proliferation

Year:  2017        PMID: 28469953      PMCID: PMC5411788     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  56 in total

Review 1.  Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.

Authors:  Nuno M F S A Cerqueira; Pedro A Fernandes; Maria J Ramos
Journal:  Recent Pat Anticancer Drug Discov       Date:  2007-01       Impact factor: 4.169

Review 2.  The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

Authors:  Antonella De Luca; Monica R Maiello; Amelia D'Alessio; Maria Pergameno; Nicola Normanno
Journal:  Expert Opin Ther Targets       Date:  2012-03-23       Impact factor: 6.902

3.  Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.

Authors:  Hao Xie; Wei Jiang; John Jiang; Yixin Wang; Richard Kim; Xiaobo Liu; Xiuli Liu
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

4.  RRM1 maintains centrosomal integrity via CHK1 and CDK1 signaling during replication stress.

Authors:  Su-Hyeon Kim; Eun-Ran Park; Hyun-Yoo Joo; Yan Nan Shen; Sung Hee Hong; Chun Ho Kim; Rachana Singh; Kee-Ho Lee; Hyun-Jin Shin
Journal:  Cancer Lett       Date:  2014-01-14       Impact factor: 8.679

Review 5.  Current progress for the use of miRNAs in glioblastoma treatment.

Authors:  Amanda Tivnan; Kerrie Leanne McDonald
Journal:  Mol Neurobiol       Date:  2013-04-28       Impact factor: 5.590

6.  CGCG clinical practice guidelines for the management of adult diffuse gliomas.

Authors:  Tao Jiang; Ying Mao; Wenbin Ma; Qing Mao; Yongping You; Xuejun Yang; Chuanlu Jiang; Chunsheng Kang; Xuejun Li; Ling Chen; Xiaoguang Qiu; Weimin Wang; Wenbin Li; Yu Yao; Shaowu Li; Shouwei Li; Anhua Wu; Ke Sai; Hongmin Bai; Guilin Li; Baoshi Chen; Kun Yao; Xinting Wei; Xianzhi Liu; Zhiwen Zhang; Yiwu Dai; Shengqing Lv; Liang Wang; Zhixiong Lin; Jun Dong; Guozheng Xu; Xiaodong Ma; Jinquan Cai; Wei Zhang; Hongjun Wang; Lingchao Chen; Chuanbao Zhang; Pei Yang; Wei Yan; Zhixiong Liu; Huimin Hu; Jing Chen; Yuqing Liu; Yuan Yang; Zheng Wang; Zhiliang Wang; Yongzhi Wang; Gan You; Lei Han; Zhaoshi Bao; Yanwei Liu; Yinyan Wang; Xing Fan; Shuai Liu; Xing Liu; Yu Wang; Qixue Wang
Journal:  Cancer Lett       Date:  2016-03-07       Impact factor: 8.679

7.  Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1.

Authors:  T Que; Y Song; Z Liu; S Zheng; H Long; Z Li; Y Liu; G Wang; Y Liu; J Zhou; X Zhang; W Fang; S Qi
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

8.  Human R1 subunit of ribonucleotide reductase (RRM1): 5' flanking region of the gene.

Authors:  N J Parker; C G Begley; R M Fox
Journal:  Genomics       Date:  1994-01-01       Impact factor: 5.736

9.  MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3).

Authors:  Chuan He Yang; Junming Yue; Susan R Pfeffer; Meiyun Fan; Elena Paulus; Amira Hosni-Ahmed; Michelle Sims; Sohail Qayyum; Andrew M Davidoff; Charles R Handorf; Lawrence M Pfeffer
Journal:  J Biol Chem       Date:  2014-07-24       Impact factor: 5.157

10.  Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal.

Authors:  Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Shanté Williams; Akihiro Otsuki; Gerard Nuovo; Abhik Raychaudhury; Herbert B Newton; E Antonio Chiocca; Sean Lawler
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

View more
  14 in total

1.  MiR-520b inhibits the development of glioma by directly targeting MBD2.

Authors:  Sitong Cui; Liang Liu; Teng Wan; Lei Jiang; Yan Shi; Liangsheng Luo
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

Review 2.  Still no Rest for the Reductases: Ribonucleotide Reductase (RNR) Structure and Function: An Update.

Authors:  Marcus J C Long; Phillippe Ly; Yimon Aye
Journal:  Subcell Biochem       Date:  2022

3.  MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5.

Authors:  Xiupeng Xu; Ning Cai; Tongle Zhi; Zhongyuan Bao; Dong Wang; Yinlong Liu; Kuan Jiang; Liang Fan; Jing Ji; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

4.  Genome-wide microRNA profiling of bovine milk-derived exosomes infected with Staphylococcus aureus.

Authors:  Mingcheng Cai; Hongbing He; Xianbo Jia; Shiyi Chen; Jie Wang; Yu Shi; Buwei Liu; Wudian Xiao; Songjia Lai
Journal:  Cell Stress Chaperones       Date:  2018-01-30       Impact factor: 3.667

5.  miR-720 is a key regulator of glioma migration and invasion by controlling TARSL2 expression.

Authors:  Yinlong Liu; Kuan Jiang; Tongle Zhi; Xiupeng Xu
Journal:  Hum Cell       Date:  2021-05-23       Impact factor: 4.174

6.  MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma.

Authors:  Zhikui Liu; Yufeng Wang; Changwei Dou; Liankang Sun; Qing Li; Liang Wang; Qiuran Xu; Wei Yang; Qingguang Liu; Kangsheng Tu
Journal:  J Exp Clin Cancer Res       Date:  2018-03-06

7.  LncRNA MALAT1/miR-129 axis promotes glioma tumorigenesis by targeting SOX2.

Authors:  Zhiyong Xiong; Luyang Wang; Qiangping Wang; Ye Yuan
Journal:  J Cell Mol Med       Date:  2018-05-29       Impact factor: 5.295

8.  MicroRNA-433 Represses Proliferation and Invasion of Colon Cancer Cells by Targeting Homeobox A1.

Authors:  Heming Li; Junfeng Li; Taisheng Yang; Shuwen Lin; Heng Li
Journal:  Oncol Res       Date:  2017-10-03       Impact factor: 5.574

9.  HOTAIRM1 competed endogenously with miR-148a to regulate DLGAP1 in head and neck tumor cells.

Authors:  Mei Zheng; Xingguang Liu; Qin Zhou; Gangli Liu
Journal:  Cancer Med       Date:  2018-06-14       Impact factor: 4.452

10.  The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities.

Authors:  Elif Damla Arisan; Alwyn Dart; Guy H Grant; Serdar Arisan; Songul Cuhadaroglu; Sigrun Lange; Pinar Uysal-Onganer
Journal:  Viruses       Date:  2020-06-04       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.